(ASRT) Assertio Therapeutics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US04546C2052
ASRT: Pain Relievers, Anti-Inflammatory, Seizure Treatment, Arthritis Medication
Assertio Holdings, Inc. (NASDAQ:ASRT) is a commercial-stage pharmaceutical company specializing in the development and marketing of therapeutic products. Its portfolio includes INDOCIN, an NSAID used for treating rheumatoid arthritis, ankylosing spondylitis, and gouty arthritis, available in oral and suppository forms. Sympazan, a benzodiazepine, is indicated for seizures in Lennox-Gastaut syndrome patients. CAMBIA, another NSAID, targets migraine symptoms, while Zipsor and SPRIX provide pain relief. Otrexup offers a single-dose methotrexate solution for rheumatoid arthritis and psoriasis. ROLVEDON, a G-CSF, reduces infection risk in febrile neutropenia. The company, rebranded in 2020, focuses on niche markets and is based in Lake Forest, Illinois.
Technically, ASRT trades at $0.82 with a 20-day volume of 351,904. The SMA20 at $0.81 and SMA50 at $0.83 suggest near-term stability, but the SMA200 at $1.07 indicates a longer-term downtrend. The ATR of $0.04 signals low volatility, implying small price movements.
Fundamentally, ASRTs market cap is $81.80M with a forward P/E of 9.78, indicating expected growth despite a current P/E of 0. The P/B of 0.57 and P/S of 0.61 suggest undervaluation, but the RoE of -52.47 highlights significant losses, raising profitability concerns.
3-Month Forecast: ASRT may face downward pressure due to poor fundamentals, with potential range-bound trading between $0.75 and $0.90. The bearish SMA200 and negative RoE could limit upside, despite the markets growth expectations reflected in the forward P/E.
Additional Sources for ASRT Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ASRT Stock Overview
Market Cap in USD | 69m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 1997-11-05 |
ASRT Stock Ratings
Growth 5y | -66.1% |
Fundamental | -32.2% |
Dividend | 0.0% |
Rel. Strength Industry | -34.3 |
Analysts | 4.5/5 |
Fair Price Momentum | 0.57 USD |
Fair Price DCF | 2.06 USD |
ASRT Dividends
No Dividends PaidASRT Growth Ratios
Growth Correlation 3m | -82.2% |
Growth Correlation 12m | -43.5% |
Growth Correlation 5y | -42.9% |
CAGR 5y | -24.75% |
CAGR/Max DD 5y | -0.27 |
Sharpe Ratio 12m | -2.28 |
Alpha | -45.21 |
Beta | 1.12 |
Volatility | 64.61% |
Current Volume | 330.2k |
Average Volume 20d | 289.8k |
As of March 15, 2025, the stock is trading at USD 0.72 with a total of 330,204 shares traded.
Over the past week, the price has changed by -7.62%, over one month by -14.18%, over three months by -23.16% and over the past year by -33.73%.
Probably not. Based on ValueRay Fundamental Analyses, Assertio Therapeutics (NASDAQ:ASRT) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -32.22 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ASRT as of March 2025 is 0.57. This means that ASRT is currently overvalued and has a potential downside of -20.83%.
Assertio Therapeutics has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy ASRT.
- Strong Buy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ASRT Assertio Therapeutics will be worth about 0.6 in March 2026. The stock is currently trading at 0.72. This means that the stock has a potential downside of -11.11%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 3 | 320.8% |
Analysts Target Price | 3.2 | 337.5% |
ValueRay Target Price | 0.6 | -11.1% |